Connective Tissue Disease Market Share

Connective Tissue Disease Market Overview

Connective Tissue Disease Market Size was valued at USD 0.24 Billion in 2023. The Global Connective Tissue Disease industry is projected to grow from USD 0.36 Billion in 2024 to USD 0.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.48% during the forecast period (2024 - 2032).

Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. 

More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.

The specific cause of this disorder is unknown but the genetic patterns are considered to escalate the risk for developing connective tissue diseases. The connective tissue diseases arises due to changes in certain genes are often known as heritable disorders of connective tissue. Some of the common inherited disorders are Ehlers-Danlos syndrome (EDS), Epidermolysis bullosa (EB), Marfan Syndrome, and Osteogenesis imperfect. 

EDS is an amalgamation of more than 10 disorders, characterized by stretchy skin, over-flexible joints, and abnormal growth of scar tissue. Various autoimmune diseases are also associated with connective tissue disorders, which includes polymyositis and dermatomyositis, rheumatoid arthritis (RA), Sjögren's syndrome, and vasculitis. Mixed connective tissue disease (MCTD) is another rare autoimmune disease, consisting of characteristic features of several diseases such as lupus, polymyositis or dermatomyositis, scleroderma, and rheumatoid arthritis. 

According to the National Center for Advancing Translational Medicines, currently there is no cure available for this condition but certain medications such as corticosteroids, immunosuppresive drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs) help in the management of symptoms. It is also stated that MCTD is more frequent in females with a male to female ratio of 1:3, and the typical age of onset of MCTD is between 15-25 years.

Notably, the Connective Tissue Disease Market is expected to expand in the near future due to the rising prevalence of various connective tissue disorders, high unmet needs of current treatment, and surge in the research and development expenditure.

Despite these drivers, there are some issues associated with connective tissue disease market. Lack of infrastructure in the middle and low income countries may hamper the growth of the market.

Intended Audience

• Hospitals


• Diagnostic clinics


• Research and Development (R&D) Companies


• Government Research Institute


• Academic Institutes and Universities 

Figure: Global Connective Tissue Disease Market, By Region Market Share, 2017 (%)

Sources: Annual reports, Press release, White paper, Company presentation

Connective Tissue Disease Market Segmentation

The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.

On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others

On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.

Connective Tissue Disease Market Regional Analysis

The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.

Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the Connective Tissue Disease Market in Europe.

Asia Pacific is the fastest growing Connective Tissue Disease Market, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.

The Middle East & Africa has the lowest Connective Tissue Disease Market due to lack of technical knowledge and poor medical facilities. 

Connective Tissue Disease Market Key Players

Some of key the players in the Connective Tissue Disease Market are: 

• Abbott Laboratories


• Bayer AG


• F. Hoffmann-La Roche Ltd


• Pfizer


• AutoImmune Inc.


• Johnson & Johnson


• Amgen Inc.


• AstraZeneca


• Eli Lilly and Company 


• Biogen


• LUPIN

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation